| Literature DB >> 33530229 |
Haili Zhang1, Hongyu Li2, Xiang Lan1, Fei Liu1, Bo Li1, Yonggang Wei1.
Abstract
ABSTRACT: Diabetes mellitus (DM) increases the risk of developing hepatocellular carcinoma (HCC), and how DM affects the prognosis of HCC have not been elucidated. The aim of this study was to compare clinicopathological characteristics and survival between hepatitis B virus (HBV)-related HCC patients with and without DM and to determine risk factors for overall survival after hepatectomy.Among 474 patients with HBV-related HCC, 119 patients had DM. Patients were divided into the diabetic group and nondiabetic group. The short-term and long-term outcomes were evaluated by using propensity score matching analysis.After 1:2 propensity score matching, there were 107 patients in diabetic group, 214 patients in nondiabetic group. The proportion of vessels invasion were higher in diabetic group. The overall survival rate in the diabetic group was 44.7% at 3 years, which was lower than that in the nondiabetic group (56.1%, P = .025). The multivariate analysis indicated that fasting blood glucose >7.0, capsular invasion, microvascular invasion and satellite were independent risk factor of poor prognosis in HCC.DM dose affect the recurrence-free survival and overall survival in HBV-related HCC patients after hepatectomy. One of the more significant findings to emerge from this study is that DM induced higher proportion of major vessel invasion in HCC patients implied unfavorable prognosis.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33530229 PMCID: PMC7850751 DOI: 10.1097/MD.0000000000024354
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Baseline characteristics of all patients before and after propensity score matching.
| Before Propensity Matching | After Propensity Matching | |||||
| Nondiabetic (n = 355) | Diabetic (n = 119) | Nondiabetic (n = 214) | Diabetic (n = 107) | |||
| Gender | .126 | .219 | ||||
| Male | 292 (82.3%) | 105 (88.2%) | 179 (83.6%) | 95 (88.8%) | ||
| Female | 63 (17.7%) | 14 (11.8%) | 35 (16.4%) | 12 (11.2%) | ||
| Age (years) | 53.1 ± 11.3 | 58.7 ± 9.7 | .000 | 57.5 ± 9.5 | 57.9 ± 9.4 | .736 |
| BMI (kg/m2) | 23.4 ± 3.0 | 24.4 ± 3.2 | .002 | 24.0 ± 3.0 | 24.3 ± 3.3 | .464 |
| Child-Pugh | .002 | 1.000 | ||||
| A | 350 (98.6%) | 111 (93.3%) | 210 (98.1%) | 105 (98.1%) | ||
| B | 5 (1.4%) | 8 (6.7%) | 4 (1.9%) | 2 (1.9%) | ||
| ALBI grade | .415 | .788 | ||||
| 1 | 275 (77.5%) | 86 (72.3%) | 159 (74.3%) | 78 (72.9%) | ||
| 2 | 79 (22.3%) | 32 (26.9%) | 55 (25.7%) | 29 (27.1) | ||
| 3 | 1 (0.2%) | 1 (0.8%) | 0 | 0 | ||
| HGB (g/L) | 141.5 ± 18.6 | 142.1 ± 18.1 | .721 | 142.1 ± 16.5 | 142.5 ± 18.2 | .858 |
| WBC (∗109) | 5.50 ± 2.1 | 5.81 ± 2.0 | .137 | 5.57 ± 2.3 | 5.62 ± 2.1 | .841 |
| PLT (∗103) | 138.2 ± 63.6 | 135.6 ± 58.9 | .680 | 134.7 ± 62.4 | 126.0 ± 62.4 | .242 |
| PT (s) | 12.23 ± 1.0 | 12.13 ± 1.5 | .507 | 12.19 ± 1.0 | 12.11 ± 1.2 | .533 |
| INR | 1.04 ± 0.13 | 1.05 ± 0.14 | .514 | 1.05 ± 0.22 | 1.05 ± 0.14 | .171 |
| ALT (IU/L) | 47.1 ± 62.6 | 48.3 ± 68.9 | .866 | 46.9 ± 66.2 | 46.8 ± 66.2 | .992 |
| FBG (mmol/L) | 5.1 ± 1.3 | 8.3 ± 3.6 | .000 | 5.15 ± 1.1 | 8.25 ± 3.4 | .000 |
| e-GRF (ml/min/1.73m2) | 99.85 ± 12.12 | 89.25 ± 21.99 | .000 | 97.49 ± 10.59 | 89.97 ± 22.54 | .018 |
| CysC (mg/L) | 0.93 ± 0.15 | 1.05 ± 0.46 | .006 | 0.94 ± 0.15 | 1.05 ± 0.48 | .003 |
| Cre (μmol/L) | 69.0 ± 13.1 | 83.4 ± 67.0 | .022 | 69.2 ± 12.4 | 82.9 ± 70.3 | .006 |
| HBV-DNA (lg) | 3.4 ± 1.7 | 3.6 ± 1.5 | .464 | 3.2 ± 1.6 | 3.5 ± 1.6 | .078 |
| AFP>400 (ng/ml) | 105 (29.7%) | 27 (22.9%) | .151 | 52 (24.3%) | 26 (24.3%) | 1.000 |
| ∗PIVKA>400 (mAU/ml) | 85 (36.0%) | 19 (31.7%) | .529 | 54 (35.5%) | 16 (32.1%) | .356 |
| ICG-R15 (%) | 6.6 ± 6.9 | 7.1 ± 5.5 | .074 | 7.62 ± 8.0 | 6.75 ± 4.8 | .284 |
AFP = alpha-fetoprotein, ALB = albumin, ALBI = albumin–bilirubin (formula: 0.085∗ALBumin/L+0.66∗lg TBμmol/L), ALT = alanine aminotransferase, BMI = body mass index, Cre = creatinine, Cys-C = Serum cystatin C, e-GFR = Estimated glomerular filtration rate, FBG = Fasting blood glucose, HBV = hepatitis B virus, HGB = Hemoglobin, ICG = indocyanine green retention rate at 15 min, INR = international normalized ratio, PIVKA = protein induced by vitamin K antagonist-II, PLT = platelet, PT = prothrombin time, TB = total bilirubin, WBC = white blood cell.
PIVKA-II testing was started in our hospital in 2016.
Pathologic characteristics of HCC in patients after propensity score matching.
| Nondiabetic (n = 214) | Diabetic (n = 107) | ||
| Tumor size (cm) | 4.1 ± 2.4 | 5.0 ± 2.9 | .014 |
| Tumor number | .928 | ||
| 1 | 178 (83.2%) | 89 (83.2%) | |
| 2 | 20 (9.3%) | 9 (8.4%) | |
| ≥3 | 16 (7.5%) | 9 (8.4%) | |
| Differentiation | .775 | ||
| Poor | 78 (36.4%) | 39 (36.4%) | |
| Moderate | 134 (62.6%) | 66 (61.7%) | |
| Well | 2 (0.9) | 2 (1.9%) | |
| Capsular invasion | 79 (36.9%) | 44 (41.1%) | .465 |
| Microvascular invasion | 46 (21.5%) | 31 (29.0%) | .139 |
| Portal vein invasion | 1 (0.5%) | 9 (8.4%) | .000 |
| Hepatic vein invasion | 0 (0.0%) | 1 (0.9%) | .157 |
| Bile duct invasion | 1 (0.5%) | 4 (3.7%) | .026 |
| satellite nodules | 15 (7.0%) | 13 (12.1%) | .124 |
| cirrhosis | 91 (42.5%) | 56 (52.3%) | .096 |
HCC = hepatocellular carcinoma.
Intra- and postoperative results of patients after propensity score matching.
| Nondiabetic (n = 214) | Diabetic (n = 107) | ||
| Blood loss (mL) | 211.0 ± 251.0 | 316.6 ± 287.1 | .001 |
| Blood transfusion | 5 (2.3%) | 9 (8.4%) | .012 |
| POD inpatient time (d) | 6.4 ± 5.1 | 8.3 ± 7.3 | .000 |
| Drainage (ml) | 376.9 ± 476.5 | 1724.5 ± 2916.6 | .000 |
| ALT (IU/L) | 345.4 ± 481.0 | 389.3 ± 400.9 | .116 |
| TB (μmol/L) | 28.4 ± 14.0 | 24.3 ± 14.4 | .001 |
| ALB (g/L) | 33.7 ± 4.7 | 32.3 ± 4.7 | .018 |
| AFP>400 (ng/mL) | 9 (4.2%) | 7 (6.5%) | .365 |
| Complications | .000 | ||
| Grade I | 172 (80.4%) | 82 (76.6%) | |
| Grade II | 39 (18.2%) | 11 (10.3%) | |
| Grade III | 0 (0.0%) | 5 (4.7%) | |
| Grade IV | 3 (1.4%) | 7 (6.5%) | |
| Grade V | 0 (0.0%) | 2 (1.9%) |
AFP = alpha-fetoprotein, ALB = albumin, ALT = alanine, aminotransferase, POD = post operation day, TB = total bilirubin.
Figure 1(A) recurrence-free survival (RFS) and (B) overall survival (OS) in patients before propensity score matching; (C) recurrence-free survival (RFS) and (D) overall survival (OS) in patients after propensity score matching.
Uni- and Multivariate risk factors of overall survival in patients after propensity score matching.
| Variable | Univariate | Multivariable | ||||
| HR | 95% CI | HR | 95% CI | |||
| Age>60 | 0.886 | 0.645–1.163 | .339 | |||
| Gender | 1.224 | 0.741–2.022 | .431 | |||
| Bmi>27 | 1.026 | 0.647–1.618 | .914 | |||
| Fasting blood glucose >7.0 | 1.524 | 1.029–2.257 | .035 | 1.489 | 1.004–2.208 | .048 |
| Tumor size>5 (cm) | 1.476 | 1.025–2.215 | .036 | |||
| Tumor number≥3 | 1.732 | 1.867–2.458 | .020 | |||
| Differentiation (poor vs moderate) | 1.096 | 0.175–1.680 | .675 | |||
| Capsular invasion | 1.881 | 1.306–2.707 | .001 | 1.553 | 1.061–2.273 | .024 |
| Microvascular invasion | 2.294 | 1.566–3.360 | .000 | 1.552 | 1.045–2.304 | .029 |
| Portal vein invasion | 2.357 | 1.145–4.852 | .020 | |||
| Bile duct invasion | 2.983 | 0.944–9.424 | .063 | |||
| Satellite | 2.204 | 1.335–3.640 | .002 | 1.861 | 1.066–3.249 | .029 |
| Ishak score = 6 | 0.939+ | 0.660–1.336 | .725 | |||
| P-AFP>400 | 1.779 | 1.160–2.731 | .008 | |||
CI = confidence interval, HR = hazard ratio, p-AFP = postoperative alpha-fetoprotein.